Dennis H. Langer, M.D., J.D., has been a Director of Brooklyn ImmunoTherapeutics since April 2021.  Dr. Langer has served as a Director of several public and private health care companies, and served in leadership positions in several pharmaceutical, biotechnology and diagnostic companies, including Chairman and Chief Executive Officer of AdvanDx, Inc. (2013-2104), Managing Partner of Phoenix IP Ventures, LLC (2005-2010), President, North America for Dr. Reddy’s Laboratories, Inc. (2004-2005), and from September 1994 until January 2004, Dr. Langer held several high-level positions at GlaxoSmithKline, and its predecessor, SmithKline Beecham, including most recently as a Senior Vice President of Research and Development.  Previously, Dr. Langer was Chief Executive Officer and a Director of Neose Technologies, Inc., and also has held R&D and marketing positions at Searle, Abbott, and Lilly. Dr. Langer currently serves on the Board of Directors of Myriad Genetics, Inc., and has served on the Boards of Dicerna Pharmaceuticals, Inc., Sirna Therapeutics, Inc. and Ception Therapeutics, Inc., which he co-founded.  Dr. Langer received a B.A. in Biology from Columbia University, an M.D. from Georgetown University School of Medicine, and a J.D. from Harvard Law School.